Closed · PA-17-112 · CFDA 93.279 · Discretionary

Neuroscience Research on Drug Abuse (R21)

Federal grant opportunity posted by National Institutes of Health, cataloged on Grants.gov.

up to $200K
Award range
Closed
Status
January 24, 2018
Close date
-
Expected awards

The verdict

Neuroscience Research on Drug Abuse (R21) is a closed discretionary listing from National Institutes of Health that offered Up to $200,000. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 12,419 other opportunities from National Institutes of Health.

up to $200K
award range
Closed
application status
93.279
CFDA program
12,419
other opportunities from National Institutes of Health

Archived opportunity record

Neuroscience Research on Drug Abuse (R21) is closed (last close January 24, 2018). The parent program page for CFDA 93.279 is the reliable place to catch re-announcements. National Institutes of Health still indexes 12,419 other opportunities here.

According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.

Deadline tracker

Application window closed

Closed January 24, 2018

Posted Jan 9 Closes Jan 24

Instrument

Grant

Description

Long-term misuse and chronic exposure to abused substances can produce widespread changes in brain structure and function. Although much progress has been made, additional research is still needed to identify the neurobiological changes that result from substance use, and how these changes contribute to substance use disorders. The overarching goals of the research areas described in this FOA are to understand the neurobiological mechanisms underlying substance use disorders, with special emphasis on identifying changes and neuroadaptations that occur during dependence, withdrawal, and relapse to chronic substance use. An understanding of the basic mechanisms underlying substance use disorders can help to identify targets for prevention and treatment interventions. Research utilizing basic, translational, or clinical approaches is appropriate.

Small-business / for-profit corridor · PA-17-112

Neuroscience Research on Drug Abuse (R21) prints a for-profit / small-business applicant door (Small businesses). Treat the listing as business-facing unless the full Grants.gov announcement narrows it further. The extract does not mark applicant cost-sharing as required. Instrument: Grant. Funding-activity codes span Education · Health (ED;HL). 789 other National Institutes of Health listings share this eligibility-code string (6% of 12,420).

Code 23
Small businesses

Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.

Official Listing on Grants.gov

View full details, application forms, and submission instructions.

View on Grants.gov

Agency Contact

NIH OER Webmaster FBOWebmaster@OD.NIH.GOV

What to do next

Neuroscience Research on Drug Abuse (R21) is closed; use the parent program and agency catalog for the next funding cycle.

  • Parent CFDA 93.279 may publish future NOFOs under the same assistance listing. Open program
  • Drug Abuse Research Programs indexes 170 Grants.gov listings in this extract. Program profile
  • National Institutes of Health lists 12,419 other indexed opportunities on PlainGrants. Agency catalog

Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.

Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.

Data sourced from the SAM.gov Assistance Listings and Grants.gov. See our methodology for details. Retrieved and formatted by PlainGrants